Clinical trials
Recurrent Vulvar Cancer clinical trials
Below are recruiting recurrent vulvar cancer clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02993900Recruiting
Brachytherapy guided by imaging for gynecologic cancers
This study tests image-guided internal radiation (brachytherapy) for certain gynecologic cancers. It may help deliver radiation more precisely by using scans done close to enrollment.
Baltimore, MarylandAges 18–100 - NCT05395962RecruitingPhase 2
Electrotherapy plus two drugs vs drug alone for vulvar cancer
This Phase 2 study compares adding electrotherapy to give carboplatin plus bleomycin directly to the tumor versus giving bleomycin alone. It may help shrink recurrent vulvar cancer when standard options aren’t suitable and your health is limited.
Bologna, BoAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05932212RecruitingPhase 2
Study drug for vulvar cancer after prior treatment failure
This Phase 2 trial tests AK104 in people with recurrent or metastatic vulvar cancer that cannot be cured with surgery or strong radiation. It may help shrink tumors or slow growth, especially if you’ve already tried standard treatments or couldn’t tolerate them.
Fuzhou, FujianAges 18–80 - NCT06029504Recruiting
Optical-guided sentinel node biopsy for vulvar cancer staging
This trial tests a new optical method using a dye to find and remove the first lymph node (sentinel node) that cancer might spread to, to stage vulvar cancer more accurately. It's for patients with a smaller tumor (under 4 cm) that hasn't been treated in the groin area before.
CopenhagenAges 18 years+ - NCT06292689RecruitingPhase 2
Cardunolizumab for advanced vulvar or vaginal cancer
This study is testing a new drug called cardunolizumab for people with advanced vulvar or vaginal cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT06495554Recruiting
Danish vulva cancer recurrence study
This study looks at how vulva cancer returns (recurrence) over time. It aims to improve follow-up care for people who have had this type of cancer.
Aarhus NAges 18 years+ - NCT06677190RecruitingPhase 2
Belzutifan for Recurrent Clear Cell Gynecologic Cancer
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Boston, MassachusettsAges 18 years+ - NCT07424664RecruitingPhase 2
Combination targeted drug and immunotherapy for recurrent gynecologic cancers
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Wuhan, HubeiAges 18–75 - NCT07443475RecruitingPhase 2
Electric field therapy for vulvar cancer that has come back
This trial tests whether a targeted electric current can improve treatment for vulvar cancer that has returned after standard therapy. The treatment uses electricity to help chemotherapy drugs enter cancer cells more effectively.
LjubljanaAges 18 years+ - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07741968Recruiting
Online program to ease fear of cancer returning
This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.
Arcadia, CaliforniaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06161428Recruiting
Dye-guided lymph node biopsy for vulvar cancer
This trial tests a new way to find and remove the first lymph node that might contain cancer cells in women with large or recurrent vulvar cancer. It uses a special dye to guide the surgeon, which may help improve staging and reduce side effects.
CopenhagenAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT07290894RecruitingPhase 2
Pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
NaplesAges 18 years+ - NCT05576831Recruiting
Testing HPV and p53 to guide vulvar cancer surgery
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
Vancouver, British ColumbiaAges 18 years+ - NCT06023862RecruitingPhase 2
Study of dostarlimab and bevacizumab for recurrent clear cell cancer
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
Clayton, Clayton Rd.Ages 18 years+ - NCT06075264RecruitingPhase 2
Artesunate ointment for high-grade vulvar lesions
This trial tests an artesunate ointment for women with high-grade vulvar lesions caused by HPV. It aims to see if the ointment can help the lesions heal or disappear without needing surgery.
Fort Myers, FloridaAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT06358469Recruiting
Vulvar cancer surgery guided by HPV and p53 testing
This trial is for people with early-stage vulvar cancer that can be surgically removed. It looks at the cancer's HPV and p53 status to decide how much tissue to remove, aiming to reduce side effects while keeping the cancer away.
Kelowna, British ColumbiaAges 18 years+ - NCT05905315RecruitingPhase 2
Vulvar cancer treatment: chemoradiation vs chemotherapy then surgery
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
AmsterdamAges 18 years+
Hear when a new Recurrent Vulvar Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent vulvar cancer?
- Yes. Clin2 currently lists 22 recruiting recurrent vulvar cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent vulvar cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent vulvar cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.